Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 200

Antibody Drugs Marketing 200

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Clinical Trials Clinical Trials Drugs 264

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Protein Medicine Drugs 147

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

Antibody 130

Antibody Drugs Medicine Development 130

Pharmaceutical Technology

MARCH 20, 2023

BioNTech has signed an exclusive worldwide licence and collaboration agreement with OncoC4 to co-develop and commercialise a new checkpoint antibody in multiple solid tumour indications. BioNTech will solely develop all the combinations other than the PD-1 inhibition.

Antibody 246

Antibody Development Trials Drugs 246

Pharmaceutical Technology

APRIL 17, 2023

Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.

Antibody 130

Antibody Engineer FDA Approval Drugs 130

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Drugs Licensing 279

Pharmaceutical Technology

DECEMBER 6, 2022

The three leading Alzheimer’s disease (AD) drugs currently in development are all monoclonal antibodies—donanemab by Eli Lilly , lecanemab by Eisai and Biogen , and gantenerumab by Roche. Monoclonal antibodies make up half of these, with an 11% share of all AD approvals.

Antibody 147

Antibody Marketing Drugs Trials 147

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Monoclonal antibody drugs for cancer. Treatment with monoclonal antibodies also helps immune systems defend against cancer.

Antibody 130

Antibody Drugs DNA Vaccination 130

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 130

Antibody Protein Drugs Licensing 130

Pharmaceutical Technology

MAY 16, 2023

Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody directed against aggregated soluble (protofibril), as well as insoluble forms of Aβ. The NDS was based on the findings obtained from the Phase IIb clinical study (Study 201) and the Phase III Clarity AD study.

Antibody 130

Antibody FDA Approval Drugs Trials 130

Pharmaceutical Technology

JANUARY 23, 2023

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Antibody 130

Antibody Medicine Drugs Development 130

Bio Pharma Dive

JUNE 16, 2021

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.

Antibody 331

Antibody Trials 331

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Medicine Drugs Licensing 130

Bio Pharma Dive

NOVEMBER 5, 2020

Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 312

Antibody Drugs 312

Pharmaceutical Technology

AUGUST 22, 2022

The World Health Organization (WHO) has made new recommendations for the usage of two monoclonal antibodies to treat the Ebola virus in its first published guideline. mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb) are the two monoclonal antibody treatments recommended by the WHO.

Antibody 147

Antibody Clinical Trials Clinical Trials Trials 147

Pharmaceutical Technology

JULY 1, 2022

Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. .

Antibody 147

Antibody Development Protein Licensing 147

Bio Pharma Dive

JUNE 18, 2021

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 347

Antibody Drugs 347

Pharmaceutical Technology

OCTOBER 18, 2022

Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Clinical Trials Clinical Trials 130

Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody 337

Antibody Drugs Development 337

Bio Pharma Dive

FEBRUARY 11, 2022

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday.

Antibody 277

Antibody 277

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. According to preliminary data, the antibody has demonstrated enhanced efficacy and reduced toxicity versus other treatments for HER2+ cancer indication. .

Antibody 130

Antibody Bioinformatics Development In-Vitro 130

Bio Pharma Dive

NOVEMBER 9, 2020

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact.

Antibody 338

Antibody Drugs 338

pharmaphorum

MAY 31, 2023

Sanofi scores in MS with CD40 antibody frexalimab Phil.Taylor Thu, 06/01/2023 - 06:39 Bookmark this

Antibody 98

Antibody 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Clinical Trials 130

Pharmaceutical Technology

JANUARY 18, 2023

The National Medical Products Administration (NMPA) of China has approved Shanghai Henlius Biotech ’s monoclonal antibody Hansizhuang (serplulimab injection) along with carboplatin and etoposide to treat extensive stage small cell lung cancer (ES-SCLC). Hansizhuang is the company’s first self-developed anti-PD-1 monoclonal antibody (mAb).

Antibody 130

Antibody Drugs Development Marketing 130

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The latest deal will grant KangaBio an exclusive licence for the use of the antibody to carry out research, development, production and marketing of immunotherapy products.

Antibody 130

Antibody Drugs Development Research 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 52

Antibody Drugs FDA Approval Marketing 52

Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody 306

Antibody Drugs Development 306

Drug Discovery World

MAY 31, 2023

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumours. “In

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. UCB6114 is a potential first-in-class antibody targeting gremlin-1, a glycoprotein secreted by the tumour stroma.

Antibody 98

Antibody Clinical Trials Clinical Trials Research 98

Bio Pharma Dive

FEBRUARY 10, 2021

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death.

Antibody 312

Antibody Drugs 312

Medical Xpress

MAY 16, 2023

Antibodies are proteins produced by our immune system, that protect us from foreign antigens that enter our body. Generally, an antibody only binds to one antigen via an epitope. These bind to antigens through epitopes, i.e., binding sites on antigens, to subsequently eliminate them.

Antibody 98

Antibody Protein 98

Bio Pharma Dive

MAY 24, 2021

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.

Antibody 321

Antibody Drugs 321

Bio Pharma Dive

NOVEMBER 5, 2020

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround.

Antibody 336

Antibody Drugs 336

Medical Xpress

MAY 10, 2023

Immunoglobulin G antibodies (IgB) play an important role as drivers of inflammation in infectious diseases and autoimmune diseases.

Antibody 105

Antibody 105